Australian Chemicals Stock News

Why Chris Mackay’s insider buying matters for MFF Capital Investments (ASX:MFF) Director Chris Mackay’s recent on-market purchase of additional MFF Capital Investments (ASX:MFF) shares puts fresh attention on insider activity, with many investors using such moves as a cue to reassess valuation and alignment. See our latest analysis for MFF Capital Investments. MFF’s A$4.72 share price has seen a modest 7 day share price return decline of 3.28% and a year to date share price return decline of...

Carmel Monaghan’s recent purchase of 2,200 shares in Regis Healthcare (ASX:REG) has drawn investor attention, as her first recorded holding directly ties boardroom incentives to shareholder outcomes and signals increased governance alignment. See our latest analysis for Regis Healthcare. Regis Healthcare’s A$6.78 share price sits against a mixed near term picture, with a 7 day share price return of 2.45% decline and a 90 day share price return of 11.83% decline, yet the 1 year and 5 year...

Austal (ASX:ASB) is back in focus after releasing half year 2025 results along with fresh fiscal 2026 EBIT guidance of about A$110 million, giving investors new detail on both recent performance and management expectations. See our latest analysis for Austal. The latest guidance and half year results land after a weak patch for the shares, with a 30 day share price return of an 18.42% decline and a 90 day share price return of a 19.17% decline, even as the 1 year total shareholder return sits...

Half year earnings drop and dividend decision come into focus Generation Development Group (ASX:GDG) has put fresh numbers on the table, with half year net income of A$6.85 million compared with A$78.88 million a year earlier, alongside an ordinary fully franked dividend of A$0.01 per share. See our latest analysis for Generation Development Group. At a share price of A$4.41, Generation Development Group has seen a 2.8% 1 day share price return, but a 30 day share price return of 11.45%...

Resolute Mining Limited recently released its full-year 2025 results, reporting net income of US$110.4 million versus a net loss of US$28.3 million a year earlier, alongside a conference presentation at the 35th BMO Global Metals, Mining & Critical Minerals Conference in Hollywood, Florida. The swing from a basic loss per share of US$0.0133 to basic earnings per share of US$0.0518 highlights a sharp turnaround in profitability that may reflect meaningful operational and cost improvements...

Ramsay Health Care Limited recently reported half-year 2025 results showing revenue of A$9,382.8 million and net profit after tax of A$160.7 million, and declared a fully franked interim dividend of A$0.425 per share for the six months ended December 31, 2025, payable on March 26, 2026. This marks a move back into profitability from a loss a year earlier, highlighting the impact of cost control efforts and portfolio optimisation on Ramsay’s earnings profile. We’ll now examine how Ramsay’s...

Dateline Resources Limited has commenced exploration at its newly acquired Music Valley Heavy Rare Earth Project in Riverside County, California, launching a high-resolution helicopter-borne magnetic and radiometric survey alongside detailed geological mapping and rock chip sampling. By engaging rare earth specialist Tony Mariano Jr and structural geologist Dr Russell Mason, the company is seeking to build a refined geological model that could pinpoint priority zones for more focused work...

The NSW Government’s backing of AGL Energy (ASX:AGL) Hunter Energy Hub through the new Investment Delivery Authority puts fresh attention on how this former coal site could shape the company’s long term energy transition plans. See our latest analysis for AGL Energy. At a share price of A$9.65, AGL Energy has seen short term share price softness, with a 1 day return of 1.73% and 7 day return of 2.43%. Its 30 day share price return of 6.87% and 3 year total shareholder return of 64.97% point...

Karoon Energy (ASX:KAR) has just packed several updates into a short window, reporting its full year 2025 results, issuing 2026 production guidance, and declaring a cash dividend of A$0.031 per share. See our latest analysis for Karoon Energy. The recent full year results, 2026 production guidance and new dividend appear to have caught the market’s attention, with a 7 day share price return of 17.48% and a 1 year total shareholder return of 23.16% at a last close of A$1.815. However, the 3...

Alkane Resources (ASX:ALK) is back in focus after director and major shareholder Bradford Mills sold 25,000,000 shares for A$42,000,000, shortly after the company reported high grade gold and antimony exploration results. See our latest analysis for Alkane Resources. Despite the recent A$1.6 share price and short term weakness, with a 1 day share price return of 3.03% decline and a 7 day share price return of 8.57% decline, Alkane Resources still shows strong momentum when you zoom out. The...

If you are wondering whether Westpac Banking's current share price still offers value, this article will walk through what the numbers are really saying about the stock. Westpac shares recently closed at A$41.00, with returns of a 3.6% decline over 7 days, 2.8% over 30 days, 5.3% year to date, 40.1% over 1 year and 119.3% over 5 years, which has many investors reassessing both its growth potential and risk profile. This article is part of our evergreen coverage of Westpac. It looks beyond...

Endeavour Group (ASX:EDV) has come into focus after releasing its half year FY26 results, which showed lower net profit, a reduced interim dividend and contrasting trends between its retail and hotels operations. See our latest analysis for Endeavour Group. At a share price of A$3.93, Endeavour Group has seen a 7.4% 1 month share price return and a 6.8% year to date share price return. However, its 1 year total shareholder return of 5.3% and 3 year total shareholder return of 35.7% underline...

PYC Therapeutics (ASX:PYC) has completed a large follow on equity offering, raising about A$584.1 million through a rights issue and a subsequent direct listing of new ordinary shares at A$1.50. See our latest analysis for PYC Therapeutics. The equity raise follows a period of mixed share price performance, with a 1 day share price return of 1.01% and a year to date share price decline of 9.37%. At the same time, a 1 year total shareholder return of 24.88% and a 3 year total shareholder...

AUB Group Limited has completed a follow-on equity offering of A$10.57 million at A$23.62 per share after reporting higher half-year revenue of A$534.83 million, net income of A$35.28 million and increased earnings per share for the period ended 31 December 2025. The company coupled its profit growth with an upgraded full-year underlying NPAT guidance range of A$220 million to A$230 million, a higher fully franked interim dividend of A$0.27 per share, active acquisition plans and the...

TPG Telecom (ASX:TPG) has just reported full year earnings and returned to a net income position of A$461 million, and also confirmed an ordinary dividend of A$0.09 per share for the half year. See our latest analysis for TPG Telecom. The earnings rebound and confirmed ordinary dividend appear to sit alongside a steady recovery in market sentiment, with a 90 day share price return of 8.60% and a 1 year total shareholder return of 32.09% pointing to momentum that has built over time rather...

A recent sell call on Xero (ASX:XRO) has put the stock in focus, with the analyst pointing to sector rotation away from higher P/E technology names and the potential for further downside until confidence improves. See our latest analysis for Xero. Despite the recent sell call, Xero’s share price has shown a short term rebound, with a 1 day share price return of 4.46% and a 30 day share price return of 8.43%. However, its year to date share price return of 21.93% and 1 year total shareholder...

Superloop’s Origin milestone puts wholesale growth and new share issuance in focus Superloop (ASX:SLC) has hit Milestone 4 in its six year Origin broadband contract after migrating more than 250,000 Origin subscribers onto its network, triggering additional share tranches tied to customer volumes. See our latest analysis for Superloop. Superloop’s recent Origin milestone sits alongside a strong 30 day share price return of 29.65% and a 12 month total shareholder return of 40.19%. The 3 year...

Why Hillgrove Resources is back on investors’ radar after its 2025 results Hillgrove Resources (ASX:HGO) has drawn fresh attention after reporting full year 2025 earnings, with sales of A$167.62 million and net income of A$0.092 million, compared with a net loss a year earlier. See our latest analysis for Hillgrove Resources. Despite the earnings turnaround, the share price has been under pressure in the short term, with a 1 month share price return of a 23.21% decline and a year to date...

Earnings shock puts 4DMedical’s losses in focus 4DMedical (ASX:4DX) reported half year earnings to 31 December 2025 that kept sales near A$2.85 million, while net loss widened to A$154.14 million and basic loss per share reached A$0.311. With revenue relatively unchanged from A$2.9 million a year earlier, the size of the current loss compared with A$11.28 million previously is likely to have investors focusing closely on cash use and expense trends. See our latest analysis for...

Upcoming call puts tungsten projects in focus American Tungsten and Antimony (ASX:AT4) has flagged a shareholder and analyst call on 25 February 2026 to outline its tungsten strategy and recent progress at projects in Utah and Nevada. The discussion will cover updates at the Dutch Mountain Tungsten Project and Processing Facility in Utah, as well as the Tennessee Mountain and Nightingale Tungsten Projects in Nevada, giving investors more detail on how these assets fit into the company’s...

In February 2026, Clinuvel Pharmaceuticals Limited reported half-year results to December 31, 2025, with revenue of A$40.56 million and net income of A$10.44 million, both lower than the same period a year earlier. The year-on-year drop in basic earnings per share from A$0.281 to A$0.2082 highlights pressure on profitability despite the company’s rare disease focus. We’ll now examine how this softer half-year revenue and earnings performance affects Clinuvel’s existing investment narrative...

Pro Medicus recently presented at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco, while co-founders Sam Hupert and Anthony Hall purchased A$3.4 million of shares on market and shareholders prepare to receive an interim dividend on March 20. Together, the insider buying and imminent cash payout highlight management’s confidence in the business and may be refocusing investors on Pro Medicus’s fundamentals despite recent technical selling pressure. With insider...

On February 26, 2026, Qantas Airways Limited announced a share repurchase program of up to A$150 million through December 31, 2026, alongside a fully franked interim dividend of A$0.198 per share following its half-year 2025 results. Taken together, the buyback and dividend signal management’s focus on returning cash to shareholders while the business remains profitable and cash-generative. Next, we’ll examine how Qantas’s new A$150 million buyback could reshape the company’s existing...

What triggered the latest focus on NEXTDC? NEXTDC (ASX:NXT) has come into focus after reporting half year results to 31 December 2025, with a net loss of A$39.35 million compared with A$42.67 million in the prior comparable period. See our latest analysis for NEXTDC. The half year result landed alongside a 1-day share price return of 1.86% and a 30-day share price return of 6.54%, while the 1-year total shareholder return is 2.78% and the 3-year total shareholder return sits at 36.73%. This...